Evidence grade: WEAK — Supported only by weak or preliminary evidence.
computed from the encoded evidence by the Atlas grading rule.
RANO-RESECT validated as prognostic in multicenter cohorts; standardizes surgical outcome reporting
Residual-tumor prognostic weight differs by molecular class; non-enhancing residual measurement is variable; supramaximal/FLAIRectomy benefit debated
Surgical trial endpoints and individual surgical goals
This is an educational research resource from Resonant Labs, not clinical advice. Evidence grades and controversies are summarized from the literature and may change as the field evolves.